



On World Arthritis Day (WAD)¹ UCB pledges its commitment to supporting the research & development of new medicines for people with rheumatic and musculoskeletal (RMD) diseases²

- **RMDs affect a quarter of all people in the European Union – over 120 million people, affecting almost every family in some way²**
- **RMDs have a huge economic burden on global healthcare systems with public spending total of €200 billion, decreased productivity and absence significantly contributing to these costs³**
- **About 1% of the population in the UK has Rheumatoid Arthritis(RA) – approximately 690,000 people⁴**

Slough, UK: 12 October 2016: Today is World Arthritis Day (WAD), a global event aimed at raising awareness of rheumatic and musculoskeletal (RMD) diseases. It is intended to raise the public's knowledge about arthritis, to influence policy makers, and to inform patients and caregivers about the support and treatment available.¹

RMDs are commonly classified into inflammatory and non-inflammatory types:

- Common non-inflammatory RMDs consist of degenerative spine diseases, osteoarthritis, osteoporosis and fibromyalgia.
- Common inflammatory RMDs consist of rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, psoriatic arthritis, connective tissue diseases and polymyalgia rheumatica.¹

UCB is a global pharmaceutical company, with expertise in two main areas of disease - immunology, which includes RMDs and those of the central nervous system, including epilepsy and Parkinson's. Our medicines treat thousands of people around the world but that doesn't mean our job is done".⁵

Scott Fleming, Communications Director, UCB, British and Irish Isles said "For us, it's vital that we listen to the constantly evolving needs of patients and their families. Working with physicians and healthcare professionals, we are engaging more with patients to better understand their clinical, economic, social and personal needs. What matters most is how they feel in their everyday life as they progress on their healthcare journey. Because we're not just treating a disease, we're caring for individual people."

He added: "At UCB we believe there is no such thing as an "average patient". We don't want to do science for science's sake, but are seeking to embed the real needs of specific patient populations in our science and innovation process. To achieve this UCB is leveraging

scientific advances and skills in areas such as genetics, biomarkers and human biology. We want to enhance our knowledge of the various expressions of a disease and the real life experience of patients so that ultimately our teams are able to deliver the right drug and the right care to the right patient. This is particularly relevant in the UK where much of our R&D is conducted across two sites by around 400 scientists.”

For further information

Scott Fleming, Communications Director
UCB, British & Irish Isles
T: +44 770.277.7378
E: scott.fleming@ucb.com

Avril O'Connor, Brand Communications Manager
UCB, British & Irish Isles
T: 07736 120044
E: avril.oconnor@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7,700 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statements - UCB

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

References:

1. World Arthritis Day About website <http://worldarthritisday.org/our-campaign>. Accessed October 2016
2. EULAR <http://www.eular.org/myUploadData/files/Q-and-A-on-RMDs.pdf> Accessed October 2016
3. World Arthritis Day RMDs Facts <http://worldarthritisday.org/facts/rmd-facts>. Accessed October 2016
4. National Rheumatoid Arthritis Society website What is RA? <http://www.nras.org.uk/what-is-ra-article>. Accessed October 2016
5. UCB website Our Vision <http://www.ucb.com/our-company/visio>. Accessed October 2016